Anti-IL-5 (Reslizumab), Humanized AntibodyDatasheet
|Synonyms:||CEP-38072, DCP 835, DCP-835, SCH-55700, SCH55700, EDF, TRF, IL5|
The research-grade biosimilar is a humanized IgG4 kappa monoclonal antibody that targets IL-5. IL-5 is a proinflammatory cytokine that mediates recruitment, activation, growth, differentiation, and survival of eosinophils. Increased production of eosinophils is associated with allergic and non-allergic forms of asthma. The antibody specifically binds to the ERRR region (between amino acids 89-92) of the IL-5, which is necessary for the interaction with the IL-5 receptor located on the eosinophil cell surface. This results in inhibition of IL-5 mediated signaling, prevents maturation of the eosinophils, and eosinophil-mediated inflammation. The original drug received approval from the FDA as an add-on treatment for patients suffering from severe asthma with an eosinophilic phenotype.